New FDA MAPP sheds light on clinical pharmacology reviews
The US Food and Drug Administration’s (FDA) Office of Translational Sciences (OTS) and the Office of Clinical Pharmacology (OCP) recently released a new manual of procedures and policies (MAPP) which outlines the good review practices (GRPs) for the clinical pharmacology review of new drug applications (NDAs) and biologics license applications (BLAs). Both offices operate under FDA’s Center for Drug Evaluation and Research (CDER).
comments(0)
5-min edit window · permanent after that